Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CTX-102
- Development stage
- Unknown
- Lead developer
- Crescita Therapeutics
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
CTX-102 is an early-stage topical drug candidate being developed by Crescita Therapeutics for the treatment of undisclosed dermatological conditions. The formulation utilizes Crescita's proprietary Multiplexed Molecular Penetration Enhancers (MMPE) technology, a platform designed to facilitate the delivery of active ingredients into or through the skin by temporarily disrupting the lipid bilayer of the stratum corneum. While the specific active ingredient and biological target are currently proprietary, CTX-102 is positioned as a delivery-enhanced small molecule therapy and is currently in Phase 1 clinical trials.
Beyond the preview
Go deeper on CTX-102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CTX-102.